Last reviewed · How we verify
Human Recombinant Regular Insulin infusion
Human Recombinant Regular Insulin infusion, marketed by Wanpen Vongpatanasin, is a currently available treatment for diabetes. The key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Human Recombinant Regular Insulin infusion |
|---|---|
| Also known as | Humulin R, National Drug Code # 0002-8501-01 |
| Sponsor | Wanpen Vongpatanasin |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Human Models of Selective Insulin Resistance: Pancreatic Clamp (PHASE1)
- Pancreatic Clamp in NAFLD (PHASE1)
- Physical Activity and Insulin Sensitivity Dynamics (NA)
- Dexamethasone/Pancreatic Clamp P&F (PHASE1)
- Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method (NA)
- Assessment of Mechanisms of Improved Wound Healing (PHASE2, PHASE3)
- Neural Mechanism of Aldosterone-induced Insulin Resistance (PHASE4)
- A Treatment Extension Study of Mucopolysaccharidosis Type IIIB (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: